FDA slow-walking the release of Pfizer’s bombshell safety document (and it’s not hard to see why)

The Pfizer document:

FDA’s forced hand drops Pfizer’s Bombshell Safety Document

The FOIA request was issued by a group of over 30 scientists and academics who filed a civil action lawsuit against the agency because they failed to fully comply with the request, since less than 1% of the documentation was released and with the FDA taking the position that all the data would be shared by 2076.

Subsequently, the governmental agency had the audacity to push the date back even further to 2096. This was due to their recent disclosure of the existence of thousands of additional pages, totaling 451,000 versus the originally stated 320,000 pages. However, the rate at which the FDA is willing to release the documentation has not changed and remains at 500 pages a month. It’s worth noting that it took the FDA only 108 days to review all of Pfizer’s documentation before authorising the Pfizer BNT162B2 vaccine for emergency authorization use on December 1, 2020.

The scientists, public health officials and academics, led by Dr Peter McCullough, formed the plaintiff group, PHMPT (Public Health and Medical Professionals for Transparency) and are being represented by the law firm of Aaron Siri, of Siri & Glimstad LLP.

I asked Siri whether FOIA requests will be made to obtain Moderna and Janssen’s (a subsidiary of Johnson and Johnson) documentation supplied to the FDA to secure emergency use authorisation. His reply: “You can’t make a request until a vaccine has been licensed. Authorization for emergency use is not the same as licensure or approval. The Pfizer vaccine is the only vaccine that’s been licensed/approved as “safe and effective” according to the FDA on August 23rd2021.”

Details about the case and the relevant court documents can be found on Aaron Siri’s blog, Injecting Freedom. The focus of this investigative report centers on the 38-page document, entitled, “Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) received through 28 February 2021.”
A sample list of the known AESIs in Pfizer’s cumulative analysis:

  • Blood and lymphatic system disorders: Lymphadenopathy
  • Cardiovascular events: acute myocardial infarction; Arrhythmia; Cardiac failure; Cardiac failure acute; Cardiogenic shock; Coronary artery disease; Myocardial infarction; Postural orthostatic tachycardia syndrome; Stress cardiomyopathy; Tachycardia
  • Gastrointestinal disorders
  • General disorders and administration site conditions
  • Infection and infestations
  • Musculoskeletal and connective tissue disorders: Arthralgia; Arthritis; Arthritis bacterial; Chronic fatigue syndrome; Polyarthritis; Polyneuropathy; Post viral fatigue syndrome; Rheumatoid arthritis
  • Nervous system disorders
  • Respiratory, thoracic, and mediastinal disorders: Lower respiratory tract infections; respiratory failures, Viral lower respiratory tract infections; acute respiratory distress syndrome; Endotracheal intubation; Hypoxia; Pulmonary hemorrhage; Respiratory disorder; Severe acute respiratory syndrome
  • Skin and subcutaneous tissue disorders
  • Anaphylaxis
  • Vaccine-Associated enhanced Disease (VAED) including Vaccine-associated enhanced respiratory disease (VAERD).
  • COVID-19
  • Facial paralysis
  • Immune-Mediated/Autoimmune disorders
  • Neurological (including demyelination): Convulsions; Ataxia; Cataplexy; Encephalopathy; Fibromyalgia; Intracranial pressure increased; Meningitis; Meningitis aseptic; Narcolepsy
  • Pregnancy-Related: Amniotic cavity infection; Caesarean section; Congenital anomaly; Death neonatal; Eclampsia; Foetal distress syndrome; Low birth weight baby; Maternal exposure during pregnancy; Placenta praevia; Pre-eclampsia; Premature labor; Stillbirth; Uterine rupture; Vasa praevia
  • Renal: Acute kidney injury, renal failure
  • Thromboembolic events: Embolism and thrombosis; Stroke AESIs, Deep vein thrombosis; Disseminated intravascular coagulation; Embolism; Embolism venous; Pulmonary embolism

To read the entire article:

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.